Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

Table 1

Comparison of pharmacokinetic parameters in steady state after intake of Pramipexole IR 1.5 mg t.i.d., Pramipexole ER 4.5 mg q.d. fasted, and Pramipexole ER 4.5 mg q.d. after fat and protein-rich meal.

	1.5 mg Pramipexole IR tablet t.i.d. (𝑛=24)		4.5 mg Pramipexole ER tablet q.d. fasted (𝑛=24)		4.5 mg Pramipexole ER tablet q.d. fed (𝑛=24)
	gMean	gCV (%)	gMean	gCV (%)	gMean	gCV (%)
AUC0-24,ss (ng⋅h/ml)	94.4	21.4	91.7	30.1	105	29.6
Cmax,ss (ng/ml)	5.3	19.0	4.9	22.3	5.9	24.7
Cpre,ss (ng/ml)	2.8	27.7	2.7	31.1	2.6	58.4

gMean: geometric Mean; gCV: geometric variation coefficient.